“Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”

Backgrounds and aims: The role of hydroxychloroquine (HCQ) in the treatment of COVID-19 is not fully known. We studied the efficacy of HCQ compared to the control in COVID-19 subjects on - a. viral clearance measured by reverse transcriptase polymerase chain reaction (RT-PCR) and, b. death due to al...

Full description

Autores:
Tipo de recurso:
Article of investigation
Fecha de publicación:
2020
Institución:
Universidad de Bogotá Jorge Tadeo Lozano
Repositorio:
Expeditio: repositorio UTadeo
Idioma:
eng
OAI Identifier:
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12148
Acceso en línea:
https://doi.org/10.1016/j.dsx.2020.05.017
http://hdl.handle.net/20.500.12010/12148
Palabra clave:
Hydroxychloroquine
COVID-19
Viral clearance
Outcomes
Death
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
Rights
License
Acceso restringido
id UTADEO2_45b6d5a7a77522e1acad608cd12431f4
oai_identifier_str oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12148
network_acronym_str UTADEO2
network_name_str Expeditio: repositorio UTadeo
repository_id_str
dc.title.spa.fl_str_mv “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
title “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
spellingShingle “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
Hydroxychloroquine
COVID-19
Viral clearance
Outcomes
Death
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
title_short “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
title_full “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
title_fullStr “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
title_full_unstemmed “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
title_sort “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
dc.subject.spa.fl_str_mv Hydroxychloroquine
COVID-19
Viral clearance
Outcomes
Death
topic Hydroxychloroquine
COVID-19
Viral clearance
Outcomes
Death
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
dc.subject.lemb.spa.fl_str_mv Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
description Backgrounds and aims: The role of hydroxychloroquine (HCQ) in the treatment of COVID-19 is not fully known. We studied the efficacy of HCQ compared to the control in COVID-19 subjects on - a. viral clearance measured by reverse transcriptase polymerase chain reaction (RT-PCR) and, b. death due to all cause. Methods: PubMed, Scopus, Cochrane and MedRxiv database were searched using the specific keywords up to April 30, 2020. Studies that met our objectives were assessed for the risk of bias applying various tools as indicated. Three studies each that reported the outcome of viral clearance by RT-PCR and death due to all cause, were meta-analyzed by applying inverse variance-weighted averages of logarithmic risk ratio (RR) using a random effects model. Heterogeneity and publication bias were assessed using the I 2 statistic and funnel plots, respectively. Results: Meta-analysis of 3 studies (n ¼ 210) on viral clearance assessed by RT-PCR showed no benefit (RR, 1.05; 95% CI, 0.79 to 1.38; p ¼ 0.74), although with a moderate heterogeneity (I2 ¼ 61.7%, p ¼ 0.07). While meta-analysis of 3 studies (n ¼ 474) showed a significant increase in death with HCQ, compared to the control (RR, 2.17; 95% 1.32 to 3.57; p ¼ 0.002), without any heterogeneity (I2 ¼ 0.0%, p ¼ 0.43). Conclusions: No benefit on viral clearance but a significant increase in mortality was observed with HCQ compared to control in patients with COVID-19.
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-08-24T15:50:41Z
dc.date.available.none.fl_str_mv 2020-08-24T15:50:41Z
dc.date.created.none.fl_str_mv 2020
dc.type.local.spa.fl_str_mv Artículo
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
format http://purl.org/coar/resource_type/c_2df8fbb1
dc.identifier.issn.spa.fl_str_mv 1871-4021
dc.identifier.other.spa.fl_str_mv https://doi.org/10.1016/j.dsx.2020.05.017
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12010/12148
dc.identifier.doi.spa.fl_str_mv https://doi.org/10.1016/j.dsx.2020.05.017
identifier_str_mv 1871-4021
url https://doi.org/10.1016/j.dsx.2020.05.017
http://hdl.handle.net/20.500.12010/12148
dc.language.iso.spa.fl_str_mv eng
language eng
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_f1cf
dc.rights.local.spa.fl_str_mv Acceso restringido
rights_invalid_str_mv Acceso restringido
http://purl.org/coar/access_right/c_f1cf
dc.format.extent.spa.fl_str_mv 8 páginas
dc.format.mimetype.spa.fl_str_mv image/jepg
dc.publisher.spa.fl_str_mv Diabetes & Metabolic Syndrome: Clinical Research & Reviews
dc.source.spa.fl_str_mv reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
instname_str Universidad de Bogotá Jorge Tadeo Lozano
institution Universidad de Bogotá Jorge Tadeo Lozano
reponame_str Expeditio Repositorio Institucional UJTL
collection Expeditio Repositorio Institucional UJTL
bitstream.url.fl_str_mv https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/1/Captura.PNG
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/3/-Hydroxychloroquine-in-patients-with-COVID_2020_Diabetes---Metabolic-Syndrom.pdf
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/2/license.txt
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/4/Captura.PNG
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/5/-Hydroxychloroquine-in-patients-with-COVID_2020_Diabetes---Metabolic-Syndrom.pdf.jpg
bitstream.checksum.fl_str_mv 143dfdd342e7fdf07b4e3fa34a270df2
8298c93dae50e65a48ea05e8cd2bf0a6
abceeb1c943c50d3343516f9dbfc110f
143dfdd342e7fdf07b4e3fa34a270df2
3bec75382606c8333a3c1eab87de1dea
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional - Universidad Jorge Tadeo Lozano
repository.mail.fl_str_mv expeditio@utadeo.edu.co
_version_ 1814213533394534400
spelling 2020-08-24T15:50:41Z2020-08-24T15:50:41Z20201871-4021https://doi.org/10.1016/j.dsx.2020.05.017http://hdl.handle.net/20.500.12010/12148https://doi.org/10.1016/j.dsx.2020.05.017Backgrounds and aims: The role of hydroxychloroquine (HCQ) in the treatment of COVID-19 is not fully known. We studied the efficacy of HCQ compared to the control in COVID-19 subjects on - a. viral clearance measured by reverse transcriptase polymerase chain reaction (RT-PCR) and, b. death due to all cause. Methods: PubMed, Scopus, Cochrane and MedRxiv database were searched using the specific keywords up to April 30, 2020. Studies that met our objectives were assessed for the risk of bias applying various tools as indicated. Three studies each that reported the outcome of viral clearance by RT-PCR and death due to all cause, were meta-analyzed by applying inverse variance-weighted averages of logarithmic risk ratio (RR) using a random effects model. Heterogeneity and publication bias were assessed using the I 2 statistic and funnel plots, respectively. Results: Meta-analysis of 3 studies (n ¼ 210) on viral clearance assessed by RT-PCR showed no benefit (RR, 1.05; 95% CI, 0.79 to 1.38; p ¼ 0.74), although with a moderate heterogeneity (I2 ¼ 61.7%, p ¼ 0.07). While meta-analysis of 3 studies (n ¼ 474) showed a significant increase in death with HCQ, compared to the control (RR, 2.17; 95% 1.32 to 3.57; p ¼ 0.002), without any heterogeneity (I2 ¼ 0.0%, p ¼ 0.43). Conclusions: No benefit on viral clearance but a significant increase in mortality was observed with HCQ compared to control in patients with COVID-19.8 páginasimage/jepgengDiabetes & Metabolic Syndrome: Clinical Research & Reviewsreponame:Expeditio Repositorio Institucional UJTLinstname:Universidad de Bogotá Jorge Tadeo LozanoHydroxychloroquineCOVID-19Viral clearanceOutcomesDeathSíndrome respiratorio agudo graveCOVID-19SARS-CoV-2Coronavirus“Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”Artículohttp://purl.org/coar/resource_type/c_2df8fbb1Acceso restringidohttp://purl.org/coar/access_right/c_f1cfKumar Singh, AwadheshSingh, AkritiSingh, RituMisra, AnoopORIGINALCaptura.PNGCaptura.PNGVer portadaimage/png190186https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/1/Captura.PNG143dfdd342e7fdf07b4e3fa34a270df2MD51open access-Hydroxychloroquine-in-patients-with-COVID_2020_Diabetes---Metabolic-Syndrom.pdf-Hydroxychloroquine-in-patients-with-COVID_2020_Diabetes---Metabolic-Syndrom.pdfArtículo reservadoapplication/pdf785405https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/3/-Hydroxychloroquine-in-patients-with-COVID_2020_Diabetes---Metabolic-Syndrom.pdf8298c93dae50e65a48ea05e8cd2bf0a6MD53embargoed access|||2200-08-24LICENSElicense.txtlicense.txttext/plain; charset=utf-82938https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/2/license.txtabceeb1c943c50d3343516f9dbfc110fMD52open accessTHUMBNAILCaptura.PNGCaptura.PNGPortadaimage/png190186https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/4/Captura.PNG143dfdd342e7fdf07b4e3fa34a270df2MD54open access-Hydroxychloroquine-in-patients-with-COVID_2020_Diabetes---Metabolic-Syndrom.pdf.jpg-Hydroxychloroquine-in-patients-with-COVID_2020_Diabetes---Metabolic-Syndrom.pdf.jpgIM Thumbnailimage/jpeg15141https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12148/5/-Hydroxychloroquine-in-patients-with-COVID_2020_Diabetes---Metabolic-Syndrom.pdf.jpg3bec75382606c8333a3c1eab87de1deaMD55open access20.500.12010/12148oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/121482020-08-24 10:50:41.485open accessRepositorio Institucional - Universidad Jorge Tadeo Lozanoexpeditio@utadeo.edu.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